Lumena Pharmaceuticals will price initial public offering of its stock

Citigroup, Cowen and Leerink Partners are joint bookrunning managers

By Devika Patel

Knoxville, Tenn., April 2 - Lumena Pharmaceuticals, Inc. plans to conduct an initial public offering of its common stock with a greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Citigroup, Cowen and Co. and Leerink Partners are the joint bookrunners.

Proceeds will be used for development and working capital, including general operating expenses and pre-commercialization activities.

The biopharmaceutical company is headquartered in San Diego. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "LIVR."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.